Institution
Tallinn University of Technology
Education•Tallinn, Estonia•
About: Tallinn University of Technology is a education organization based out in Tallinn, Estonia. It is known for research contribution in the topics: European union & Computer science. The organization has 3688 authors who have published 10313 publications receiving 145058 citations. The organization is also known as: Tallinn Technical University & Tallinna Tehnikaülikool.
Topics: European union, Computer science, Oil shale, Nonlinear system, Thin film
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The amyloid cascade hypothesis is revisited demonstrating the possible roles of Zn(II) and Cu(II), thus influencing the fibrillization and toxicity of Aβ in AD.
75 citations
••
TL;DR: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg vs. rosuvastsatin (ROSVastatin) 10’mg.
Abstract: SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patients were randomised to EZE ⁄SIMVA 10 ⁄20 mg (n = 314) or ROSUVA 10 mg (n = 304) for 6 weeks. Results: EZE ⁄SIMVA produced greater reductions in LDL-C ()27.7% vs. )16.9%; p £ 0.001), total cholesterol ()17.5% vs. )10.3%; p £ 0.001), non-high-density lipoprotein cholesterol (HDL-C) ()23.4% vs. )14.0%; p £ 0.001) and apolipoprotein B ()17.9% vs. )9.8%; p £ 0.001) compared with ROSUVA, while both treatments were equally effective at increasing HDL-C (2.1% vs. 3.0%; p = 0.433). More patients achieved LDL-C levels < 2.59 mmol ⁄l (73% vs. 56%), < 2.00 mmol ⁄l (38% vs. 19%) and < 1.81 mmol ⁄l (25% vs. 11%) with EZE ⁄SIMVA than ROSUVA (p £ 0.001). A borderline significantly greater reduction in triglycerides (p = 0.056) was observed for EZE ⁄SIMVA ()11.0%) vs. ROSUVA ()5.3%). There were no between-group differences in the incidences of adverse events or liver transaminase and creatine kinase elevations. Conclusion: EZE ⁄SIMVA 10 ⁄20 mg produced greater improvements in LDL-C, total cholesterol, non-HDL-C and apoB with a similar safety profile as for ROSUVA 10 mg. What’s known • Optimal management of plasma LDL-C levels is the primary goal of therapeutic intervention in patients at risk of coronary events. • A substantial proportion of patients at risk of coronary events fail to achieve recommended LDL-C goals with statin monotherapy and are therefore at increased risk of future coronary events.
75 citations
••
TL;DR: In this article, the nitritation-anaerobic ammonium oxidation (anammox) process was studied for the first time using an oxidation-reduction potential (ORP) decrease rate control.
Abstract: The nitritation–anaerobic ammonium oxidation (anammox) process was studied for the first time using an oxidation–reduction potential (ORP) decrease rate control in the anammox sequencing b...
75 citations
••
TL;DR: In animal models of PD, CDNF protects and repairs DA neurons, regulates ER stress, and improves motor function more efficiently than other NTFs.
74 citations
••
TL;DR: In this paper, the results showed that P. placenta tended to degrade cellulose amorphous regions more readily, while C. puteana, possessing full enzyme complement, was able to degrade both amorphus and crystalline regions more easily.
74 citations
Authors
Showing all 3757 results
Name | H-index | Papers | Citations |
---|---|---|---|
James Chapman | 82 | 483 | 36468 |
Alexandre Alexakis | 67 | 540 | 17247 |
Bernard Waeber | 56 | 370 | 35335 |
Peter A. Andrekson | 54 | 573 | 12042 |
Charles S. Peirce | 51 | 167 | 11998 |
Lars M. Blank | 49 | 301 | 8011 |
Fushuan Wen | 49 | 465 | 9189 |
Mati Karelson | 48 | 207 | 10210 |
Ago Samoson | 46 | 119 | 8807 |
Zebo Peng | 45 | 359 | 7312 |
Petru Eles | 44 | 300 | 6749 |
Vijai Kumar Gupta | 43 | 301 | 6901 |
Eero Vasar | 43 | 263 | 6930 |
Rik Ossenkoppele | 42 | 192 | 6839 |
Tõnis Timmusk | 41 | 105 | 11056 |